JP2023531494A5 - - Google Patents

Info

Publication number
JP2023531494A5
JP2023531494A5 JP2022578997A JP2022578997A JP2023531494A5 JP 2023531494 A5 JP2023531494 A5 JP 2023531494A5 JP 2022578997 A JP2022578997 A JP 2022578997A JP 2022578997 A JP2022578997 A JP 2022578997A JP 2023531494 A5 JP2023531494 A5 JP 2023531494A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
sequence
polypeptide
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022578997A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023531494A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/039006 external-priority patent/WO2021263058A1/en
Publication of JP2023531494A publication Critical patent/JP2023531494A/ja
Publication of JP2023531494A5 publication Critical patent/JP2023531494A5/ja
Priority to JP2025145375A priority Critical patent/JP2026004299A/ja
Pending legal-status Critical Current

Links

JP2022578997A 2020-06-25 2021-06-24 Her-2標的化二重特異性組成物ならびにその作製および使用のための方法 Pending JP2023531494A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025145375A JP2026004299A (ja) 2020-06-25 2025-09-02 Her-2標的化二重特異性組成物ならびにその作製および使用のための方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063044301P 2020-06-25 2020-06-25
US63/044,301 2020-06-25
US202063077503P 2020-09-11 2020-09-11
US63/077,503 2020-09-11
US202063108783P 2020-11-02 2020-11-02
US63/108,783 2020-11-02
US202163166857P 2021-03-26 2021-03-26
US63/166,857 2021-03-26
US202163196408P 2021-06-03 2021-06-03
US63/196,408 2021-06-03
PCT/US2021/039006 WO2021263058A1 (en) 2020-06-25 2021-06-24 Her-2 targeted bispecific compositions and methods for making and using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025145375A Division JP2026004299A (ja) 2020-06-25 2025-09-02 Her-2標的化二重特異性組成物ならびにその作製および使用のための方法

Publications (2)

Publication Number Publication Date
JP2023531494A JP2023531494A (ja) 2023-07-24
JP2023531494A5 true JP2023531494A5 (https=) 2024-09-25

Family

ID=79281898

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022578997A Pending JP2023531494A (ja) 2020-06-25 2021-06-24 Her-2標的化二重特異性組成物ならびにその作製および使用のための方法
JP2025145375A Pending JP2026004299A (ja) 2020-06-25 2025-09-02 Her-2標的化二重特異性組成物ならびにその作製および使用のための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025145375A Pending JP2026004299A (ja) 2020-06-25 2025-09-02 Her-2標的化二重特異性組成物ならびにその作製および使用のための方法

Country Status (12)

Country Link
US (2) US20230322922A1 (https=)
EP (1) EP4172179A4 (https=)
JP (2) JP2023531494A (https=)
KR (1) KR20230041711A (https=)
AU (2) AU2021297984C1 (https=)
BR (1) BR112022026420A2 (https=)
CA (1) CA3182372A1 (https=)
CO (1) CO2023000247A2 (https=)
IL (1) IL298815A (https=)
MX (1) MX2022016387A (https=)
PH (1) PH12022553407A1 (https=)
WO (1) WO2021263058A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230041711A (ko) 2020-06-25 2023-03-24 아뮤닉스 파마슈티컬스, 인크. Her-2 표적화 이중특이적 조성물 및 이의 제조 및 사용 방법
KR20250133776A (ko) 2023-02-10 2025-09-08 아뮤닉스 파마슈티컬스, 인크. 전립선-특이적 막 항원(psma)을 표적화하는 조성물 및 이의 제조 방법 및 사용 방법
CN121949565A (zh) 2023-04-17 2026-05-01 阿穆尼克斯制药公司 靶向表皮生长因子受体的组合物及其制备和使用方法
WO2025122957A1 (en) 2023-12-08 2025-06-12 Amunix Pharmaceuticals, Inc. Protease activatable cytokines and methods for making and using the same
GB2641580A (en) * 2024-06-07 2025-12-10 T Therapeutics Ltd Tumour-transforming multispecific proteins
WO2026024863A2 (en) 2024-07-24 2026-01-29 Amunix Pharmaceuticals, Inc. Compositions targeting prostate-specific membrane antigen (psma) in combination with androgen receptor antagonists

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992518A (en) 1974-10-24 1976-11-16 G. D. Searle & Co. Method for making a microsealed delivery device
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4284444A (en) 1977-08-01 1981-08-18 Herculite Protective Fabrics Corporation Activated polymer materials and process for making same
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4200984A (en) 1979-03-12 1980-05-06 Fink Ray D Detachable tool combining bracket and method
US4398908A (en) 1980-11-28 1983-08-16 Siposs George G Insulin delivery system
US4435173A (en) 1982-03-05 1984-03-06 Delta Medical Industries Variable rate syringe pump for insulin delivery
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US5231112A (en) 1984-04-12 1993-07-27 The Liposome Company, Inc. Compositions containing tris salt of cholesterol hemisuccinate and antifungal
ATE59302T1 (de) 1984-07-24 1991-01-15 Key Pharma Klebende schicht zur transdermalen freigabe.
US4684479A (en) 1985-08-14 1987-08-04 Arrigo Joseph S D Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures
US6759057B1 (en) 1986-06-12 2004-07-06 The Liposome Company, Inc. Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
IE60901B1 (en) 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
US4933185A (en) 1986-09-24 1990-06-12 Massachusetts Institute Of Technology System for controlled release of biologically active compounds
US6406713B1 (en) 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
US4976696A (en) 1987-08-10 1990-12-11 Becton, Dickinson And Company Syringe pump and the like for delivering medication
US4861800A (en) 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
AU598958B2 (en) 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
GB8807504D0 (en) 1988-03-29 1988-05-05 Sandoz Ltd Improvements in/relating to organic compounds
JP2717808B2 (ja) 1988-08-10 1998-02-25 テルモ株式会社 シリンジポンプ
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5017378A (en) 1989-05-01 1991-05-21 The University Of Virginia Alumni Patents Foundation Intraorgan injection of biologically active compounds contained in slow-release microcapsules or microspheres
US5298022A (en) 1989-05-29 1994-03-29 Amplifon Spa Wearable artificial pancreas
US5492534A (en) 1990-04-02 1996-02-20 Pharmetrix Corporation Controlled release portable pump
US5318540A (en) 1990-04-02 1994-06-07 Pharmetrix Corporation Controlled release infusion device
US5176502A (en) 1990-04-25 1993-01-05 Becton, Dickinson And Company Syringe pump and the like for delivering medication
US5215680A (en) 1990-07-10 1993-06-01 Cavitation-Control Technology, Inc. Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5573776A (en) 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US5660848A (en) 1994-11-02 1997-08-26 The Population Council, Center For Biomedical Research Subdermally implantable device
ATE252372T1 (de) 1996-08-23 2003-11-15 Sequus Pharm Inc Liposome enthaltend cisplatin
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
JP2001503396A (ja) 1996-10-11 2001-03-13 アルザ コーポレイション 治療用リポソーム組成物および方法
HUP0000522A3 (en) 1996-10-15 2000-10-30 Transave Inc Monmouth Junction N-acyl phoshpatidylethanolamine-mediated liposomal drug delivery
US6361796B1 (en) 1996-10-25 2002-03-26 Shire Laboratories, Inc. Soluble form osmotic dose delivery system
DE69735002T2 (de) 1996-10-25 2006-10-26 Shire Laboratories, Inc. Osmotisches Verabreichungssystem für lösliche Dosen
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
DE19747261A1 (de) 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
ES2255155T3 (es) 1998-02-05 2006-06-16 Biosense Webster, Inc. Dispositivo para la administracion intracardiaca de farmacos.
US6406632B1 (en) 1998-04-03 2002-06-18 Symyx Technologies, Inc. Rapid characterization of polymers
GB9815157D0 (en) 1998-07-13 1998-09-09 Metron Designs Ltd High resolution pulse width setting from relatively low frequency clocks
US6713086B2 (en) 1998-12-18 2004-03-30 Abbott Laboratories Controlled release formulation of divalproex sodium
CN1736502A (zh) 1999-03-03 2006-02-22 奥普蒂诺斯公司 鼻传送装置
US6183770B1 (en) 1999-04-15 2001-02-06 Acutek International Carrier patch for the delivery of agents to the skin
US6743211B1 (en) 1999-11-23 2004-06-01 Georgia Tech Research Corporation Devices and methods for enhanced microneedle penetration of biological barriers
US6352721B1 (en) 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
US20030228309A1 (en) 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
IN190699B (https=) 2001-02-02 2003-08-16 Sun Pharmaceutical Ind Ltd
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
CA2445860A1 (en) 2001-04-30 2002-11-07 Shire Laboratories Inc. Pharmaceutical composition including ace/nep inhibitors and bioavailability enhancers
US6838093B2 (en) 2001-06-01 2005-01-04 Shire Laboratories, Inc. System for osmotic delivery of pharmaceutically active agents
KR100407467B1 (ko) 2001-07-12 2003-11-28 최수봉 리모컨 방식의 인슐린 자동주사기
US6945952B2 (en) 2002-06-25 2005-09-20 Theraject, Inc. Solid solution perforator for drug delivery and other applications
US7294513B2 (en) 2002-07-24 2007-11-13 Wyatt Technology Corporation Method and apparatus for characterizing solutions of small particles
CA2569509C (en) 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
CN101309703A (zh) 2005-09-12 2008-11-19 诺维莫尼公司 抗cd3抗体组合物
EP2370467B1 (en) 2008-10-01 2016-09-07 Amgen Research (Munich) GmbH Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
ES2610356T3 (es) 2009-02-03 2017-04-27 Amunix Operating Inc. Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
KR101813727B1 (ko) 2009-06-08 2018-01-02 아뮤닉스 오퍼레이팅 인코포레이티드 성장 호르몬 폴리펩타이드 및 이를 제조하고 사용하는 방법
WO2010144508A1 (en) 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
WO2011028344A2 (en) 2009-08-25 2011-03-10 Amunix Operating Inc. Interleukin-1 receptor antagonist compositions and methods of making and using same
ES2993140T3 (en) 2010-04-02 2024-12-23 Amunix Pharmaceuticals Inc Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
US8557961B2 (en) 2010-04-02 2013-10-15 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
CN104661674A (zh) 2012-07-11 2015-05-27 阿穆尼克斯运营公司 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子viii-xten融合物及其用途
MX2017006016A (es) * 2014-11-11 2017-06-19 Amunix Operating Inc Composiciones conjugadas de xten direccionadas y metodos para producir las mismas.
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
AU2018393111B2 (en) 2017-12-21 2025-07-10 Amunix Pharmaceuticals, Inc. Release segments and binding compositions comprising same
JP7337079B2 (ja) * 2018-02-15 2023-09-01 マクロジェニクス,インコーポレーテッド 変異型cd3結合ドメイン、及び疾患の治療のための併用療法におけるその使用
MX2021015882A (es) 2019-06-26 2022-04-18 Amunix Pharmaceuticals Inc Fragmentos de unión a antígeno egfr y composiciones que los comprenden.
CA3143519A1 (en) 2019-06-26 2020-12-30 Volker Schellenberger Cd3 antigen binding fragments and compositions comprising same
JP7725466B2 (ja) * 2019-11-13 2025-08-19 アムニクス ファーマシューティカルズ, インコーポレイテッド バーコード化されたxtenポリペプチドおよびその組成物、ならびにその作製および使用方法
KR20230041711A (ko) 2020-06-25 2023-03-24 아뮤닉스 파마슈티컬스, 인크. Her-2 표적화 이중특이적 조성물 및 이의 제조 및 사용 방법

Similar Documents

Publication Publication Date Title
JP2023531494A5 (https=)
EP3571225B1 (en) Improved serum albumin binders
AU2016357460B2 (en) Improved serum albumin binders
EP3571224B1 (en) Improved serum albumin binders
AU2016351710B2 (en) Improved serum albumin-binding immunoglobulin variable domains
CN103619878B (zh) 结合血清白蛋白的蛋白
AU2014202764B2 (en) Improved anti-serum albumin binding variants
IL310340A (en) Improved serum albumin binding immunoglobulin single variable domains
JP6100315B2 (ja) 改良型抗血清アルブミン結合変異体
JP2022538222A5 (https=)
JP2025512865A5 (https=)
JP2016027801A (ja) 改良された抗血清アルブミン結合変異体
JP2025517360A (ja) トランスフェリン受容体結合ドメイン及びそれを含むタンパク質
CN114805568B (zh) 靶向人lilrb2的纳米抗体及其应用
CN116333128B (zh) 靶向人lilrb2的纳米抗体及其应用
HK40117444A (en) Improved serum albumin binders
HK40118030A (en) Improved serum albumin binders
WO2025068449A1 (en) Knob domain proteins
HK40116819A (en) Improved serum albumin binders
HK40119626A (en) Improved serum albumin binders
HK40017968A (en) Improved serum albumin binders
HK40017968B (en) Improved serum albumin binders
HK40018516A (en) Improved serum albumin binders
HK40018516B (en) Improved serum albumin binders